A study gathering data from three clinical trials showed that PROs can be a prognosis for overall survival [17], but there is limited data examining PROs from patients with metastatic HER2-positive breast cancer, which includes the patients’ needs and the impact of the disease on their QoL. The gene discussed is ERBB2; the disease is breast carcinoma.